Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.
Joanne M BowenRachel J GibsonJanet K CollerNicole BlijlevensPaolo BossiNoor Al-DasooqiEmma H BatemanKaren ChiangCharlotte de MooijBronwen MayoAndrea M StringerWim TissingHannah R WardillYsabella Z A van SebilleVinisha RannaAnusha VaddiDorothy Mk KeefeRajesh V LallaKaris Kin Fong ChengSharon Eladnull nullPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)
Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.